Ascendis Pharma As Stock Probability of Future Stock Price Finishing Over 0.38

ASND Stock  USD 129.90  3.24  2.56%   
Ascendis Pharma's future price is the expected price of Ascendis Pharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Ascendis Pharma AS performance during a given time horizon utilizing its historical volatility. Check out Ascendis Pharma Backtesting, Ascendis Pharma Valuation, Ascendis Pharma Correlation, Ascendis Pharma Hype Analysis, Ascendis Pharma Volatility, Ascendis Pharma History as well as Ascendis Pharma Performance.
  
The current year's Price Earnings To Growth Ratio is expected to grow to 0.79, whereas Price To Sales Ratio is forecasted to decline to 22.84. Please specify Ascendis Pharma's target price for which you would like Ascendis Pharma odds to be computed.

Ascendis Pharma Target Price Odds to finish over 0.38

The tendency of Ascendis Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 0.38  in 90 days
 129.90 90 days 0.38 
close to 99
Based on a normal probability distribution, the odds of Ascendis Pharma to stay above $ 0.38  in 90 days from now is close to 99 (This Ascendis Pharma AS probability density function shows the probability of Ascendis Stock to fall within a particular range of prices over 90 days) . Probability of Ascendis Pharma AS price to stay between $ 0.38  and its current price of $129.9 at the end of the 90-day period is about 31.11 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.17 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Ascendis Pharma will likely underperform. Additionally Ascendis Pharma AS has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Ascendis Pharma Price Density   
       Price  

Predictive Modules for Ascendis Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ascendis Pharma AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ascendis Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
126.55129.95133.35
Details
Intrinsic
Valuation
LowRealHigh
62.5565.95142.89
Details
Naive
Forecast
LowNextHigh
113.78117.17120.57
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-2.2-1.640.63
Details

Ascendis Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Ascendis Pharma is not an exception. The market had few large corrections towards the Ascendis Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ascendis Pharma AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ascendis Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.13
β
Beta against Dow Jones1.17
σ
Overall volatility
9.49
Ir
Information ratio -0.04

Ascendis Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ascendis Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ascendis Pharma AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Ascendis Pharma AS generated a negative expected return over the last 90 days
Ascendis Pharma AS has high historical volatility and very poor performance
The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 39.04 M.
Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11.
Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures
Over 99.0% of the company shares are held by institutions such as insurance companies
Latest headline from benzinga.com: Heres How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

Ascendis Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ascendis Stock often depends not only on the future outlook of the current and potential Ascendis Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ascendis Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding56.3 M
Cash And Short Term Investments399.4 M

Ascendis Pharma Technical Analysis

Ascendis Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Ascendis Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Ascendis Pharma AS. In general, you should focus on analyzing Ascendis Stock price patterns and their correlations with different microeconomic environments and drivers.

Ascendis Pharma Predictive Forecast Models

Ascendis Pharma's time-series forecasting models is one of many Ascendis Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Ascendis Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Ascendis Pharma AS

Checking the ongoing alerts about Ascendis Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Ascendis Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Ascendis Pharma AS generated a negative expected return over the last 90 days
Ascendis Pharma AS has high historical volatility and very poor performance
The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 39.04 M.
Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11.
Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures
Over 99.0% of the company shares are held by institutions such as insurance companies
Latest headline from benzinga.com: Heres How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.37)
Revenue Per Share
5.595
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.28)
Return On Equity
(8.18)
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.